Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as balstilimab, Anti-PD-1, Balstilimab (BAL)
AGEN2034 · 8 trials · 21 indications
Comparison of survival of patients under Botensilimab + Balstilimab versus the standard of care FOLFOX/XELOX + nivolumab
Unacceptable toxicity rate in cycle 1 of \< 33%
Overall survival and progression-free survival at 12 and 18 months, as well as median progression-free and overall survival.
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) assessed per the Lugano criteria
Determine the progression-free survival rate at 6 months of combination therapy with doxorubicin, AGEN1884, and AGEN2034 in anthracycline-naïve patients with advanced or metastatic soft tissue sarcomas.
Phase 1: To determine the recommended phase 2 dose of ivermectin in combination with balstilimab or pembrolizumab using NCI-CTCAE v5.0
Phase 2: To determine the efficacy of ivermectin in combination with balstilimab or pembrolizumab in mTNBC and HR+/HER2- MBC using the objective response rate (ORR)
Incidence of TEAEs using NCI CTCAE v5.0
Proportion of patients who have achieved CR, PR, or stable disease (SD) per RECIST 1.1 / iRECIST during the Dose Escalation part
A DLT was defined as any treatment-related toxicity that was National Cancer Institute Common Terminology Criteria for Adverse Event Grade ≥3, confirmed by the safety monitoring committee to be relevant for the study drug treatment, and that occurred during the first 3 weeks of balstilimab treatment in the dose escalation portion of the study (DLT evaluation period).
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. TEAEs were AEs with onset dates during the on-treatment period, or the worsening of an event during the on-treatment period. A summary of all Serious Adverse Events and Other Adverse Events (nonserious), regardless of causality, is located in the 'Reported Adverse Events' Section.
ORR was defined as percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), as determined by an IERC per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). BOR was defined as the best response recorded from the start of the study treatment until the end of treatment. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| Arm | Type | Description |
|---|---|---|
| Best Supportive Care | ACTIVE_COMPARATOR | - |
| Botensilimab + Balstilimab and Best Supportive Care | EXPERIMENTAL | - |
| Experimental arm | EXPERIMENTAL | Patients treated with Botensilimab + Balstilimab |
| Standard arm | ACTIVE_COMPARATOR | o FOLFOX\*, IV, Q2W + Nivolumab 240mg, IV, Q2. \*FOLFOX = oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks. Premedication is not usually required in the first cycle. For subsequent cycles, adequate premedication may be administrated per local standard. OR * XELOX\*, IV, Q3W + Nivolumab (360 mg, IV, Q3W). XELOX = Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks * Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression. |
| Blood-brain barrier opening with concomitant BAL, BOT, DOX | EXPERIMENTAL | Patients will undergo implantation of Sonocloud-9 after completion of radiotherapy. Within 21 days after implant, ultrasound-based BBB opening with concomitant administration of DOX (30 mg) + BAL (450 mg) every 3 weeks, and BOT (dose 1mg/kg) every 6 weeks will be initiated. |
| Balstilimab | EXPERIMENTAL | 300 mg IV every 3 weeks for a maximum of 24 months |
| Part 1: Stage 1, Safety Lead-In | EXPERIMENTAL | The safety lead-in will enroll 6 participants. Balstilimab 300mg flat q3 weeks up to 2 years; Zalifrelimab 1mg/kg q6 weeks x 4; Doxorubicin 75mg/m2 q3 weeks x 2, starts at C2 The participants will complete a dose-limiting toxiciy (DLT) observation period of 9 weeks. |
| Part 1: Stage 2, Expansion | EXPERIMENTAL | Balstilimab 300mg flat q3 weeks up to 2 years; Zalifrelimab 1mg/kg q6 weeks up to 2 years; Doxorubicin 75mg/m2 q3 weeks x 6 |
| Part 2: Stage 2, Dose 1 | EXPERIMENTAL | Doxorubicin 60mg/m2 q3 weeks x 6 doses Botensilimab 75mg q6 weeks up to two years |
| Stage 2, Dose 2 | EXPERIMENTAL | Doxorubicin 75mg/m2 q3 weeks x 6 doses Botensilimab 75mg q6 weeks up to two years |
| Stage 2, Dose 3 Combination of Doxorubicin with Botensilimab and Balstilimab | EXPERIMENTAL | Doxorubicin 75mg/m2 q3 weeks x 6 doses Botensilimab 75mg flat q6 weeks up to 2 years Balstilimab 450mg q3 weeks up to 2 years |
| Treatment (ivermectin, balstilimab) | EXPERIMENTAL | Patients will receive balstilimab 450 mg or pembrolizumab 200 mg, IV, on Day 1 of each 3 week cycle and ivermectin at the assigned dose (see Section 5.1, Table 5.1.2), PO, Days 1-3, 8-10, 15-17 of each cycle (Days 1-3 of each week) until disease progression, intolerable toxicities, withdrawal of consent, or up to 35 treatments or 2 years of balstilimab or pembrolizumab, whichever comes first |
| 30 mg (Dose Level 1) | EXPERIMENTAL | 14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 30 mg twice a day for 14 days |
| 90 mg (Dose Level 2) | EXPERIMENTAL | 14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days |
| 180 mg (Dose Level 3) | EXPERIMENTAL | 14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 180 mg twice a day for 14 days |
| other mGI cancers | EXPERIMENTAL | 14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days |
| Expansion in MSS/pMMR mCRC patients | EXPERIMENTAL | 14-day cycles of combined AGEN2034 3 mg/Kg iv on D1 of each cycle, and oral CR6086 90 mg twice a day for 14 days |
| Monotherapy | EXPERIMENTAL | Dose of 3 mg/kg intravenous (IV) every 2 weeks for up to 24 months. |
| Name | Type | Description |
|---|---|---|
| Best Supportive Care | OTHER | Measures designed to provide palliation of symptoms and improve quality of life as much as possible |
| Balstilimab | DRUG | 450mg IV every 3 weeks |
| Botensilimab | DRUG | 75mg IV every 6 weeks x 4 doses |
| Folfox Protocol | DRUG | oxaliplatin 85 mg/m2 , leucovorin 400 mg/m2 , and fluorouracil 400 mg/m2 administered IV on Day 1 of each treatment cycle, and fluorouracil 1200 mg/m2 IV continuous infusion over 24 hours daily or per local standard on Days 1 and 2 of each treatment cycle, every 2 weeks.Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression. |
| XELOX | DRUG | Oxaliplatin 130mg/m² IV on Day 1 of each treatment cycle + capecitabine 1000mg/m² orally twice daily on Days 1 to 14 of each treatment cycle, every 3 weeks. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression. |
| Nivolumab | DRUG | 240mg, IV, Q2. Treatment is recommended until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression. |
| Liposomal Doxorubicin | DRUG | Liposomal Doxorubicin 30 mg IV over 30 minutes every 3 weeks |
| Sonocloud-9 (SC-9) | DEVICE | Device activation of 9 ultrasound emitters during IV injection of microbubbles every 3 weeks |
| Zalifrelimab | DRUG | Zalifrelimab (AGEN1884) is a fully human monoclonal immunoglobulin G1 κ subclass (IgG1κ) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152). Zalifrelimab (AGEN1884) is being developed as a monotherapy for cancer indications with potential for future development in combination with other immunotherapies. |
| Doxorubicin | DRUG | Doxorubicin is the standard of care first-line therapy for most subtypes of metastatic soft tissue sarcomas. Doxorubicin monotherapy administered at 75 mg/m2 has resulted in objective response rate of 14%, and median progression-free survival of 4.6 months, and another study reported progression-free survival at 6 months of 46.3%, with a median PFS of 5.8 months, and best objective response rate of 19%. |
| Ivermectin | DRUG | Ivermectin at the assigned dose administered PO on Days 1-3, 8-10, 15-17 of each 21 day cycle (Days1-3 of each week). |
| Balstilmab | DRUG | Balstilimab 300 mg administered intravenously on Day 1 of each 21 day cycle. |
| Pembrolizumab | DRUG | Pembrolizumab 200 mg IV on Day 1 of each 21 day cycle |
| CR6086 | DRUG | oral CR6086, twice a day for 14 days |
| AGEN2034 | BIOLOGICAL | AGEN2034 3 mg/Kg iv on D1 of each 14- day cycle |
Inclusion Criteria: * Must have histologically confirmed colorectal adenocarcinoma that is not deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H). * Received and failed all prior available therapies, such that the standard of care for the patient would be best supportive ca...
Top 5 of 9 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE2 | Durvalumab |
| Nanobiotix SA Sponsored ADR | NBTX | 1 | PHASE1 | NBTXR3 |
| Olema Pharmaceuticals, Inc. | OLMA | 1 | PHASE1 | OP-3136, Palazestrant |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
| Pfizer Inc. | PFE | 1 | N/A | Palbociclib |
AGEN2034 is an investigational monoclonal antibody being developed by Agenus Inc. for the treatment of advanced cancer. It is in Phase 1 clinical development and has been studied in advanced tumors, cervical cancer, and refractory metastatic colorectal cancer. AGEN2034 is also known as balstilimab.
AGEN2034 is being studied for advanced cancer, including refractory metastatic colorectal cancer, metastatic microsatellite-stable colorectal cancer, and other metastatic gastrointestinal cancers, as well as cervical cancer. It is investigational and has not been approved for any indication.
AGEN2034 targets PD-1, a protein that acts as an immune checkpoint. By binding to PD-1, the monoclonal antibody is designed to block checkpoint signaling and support an immune response against tumor cells. This mechanism is being evaluated in Phase 1 studies in advanced solid tumors.
AGEN2034 is being developed by Agenus Inc., a biopharmaceutical company whose common stock trades on the Nasdaq under the ticker AGEN. Agenus is the sponsor of the clinical program evaluating AGEN2034 in advanced cancers.
AGEN2034 is in Phase 1 clinical development. It is an investigational agent and has not been approved by the FDA for any indication. The program includes one active trial and one completed trial, with a combined enrollment of 211 participants.
AGEN2034 has been evaluated in two Phase 1 trials. NCT03104699 studied AGEN2034 in advanced tumors and cervical cancer and is completed. NCT05205330 is testing balstilimab (AGEN2034) in combination with vorbipiprant (CR6086) in refractory metastatic colorectal cancer and other metastatic gastrointestinal cancers, and is active but not recruiting.
Yes, AGEN2034 is also known as balstilimab. Both names refer to the same investigational monoclonal antibody developed by Agenus Inc. that targets PD-1. The alternative name appears in the trial listing for NCT05205330, which evaluates balstilimab in combination with vorbipiprant.